Changes in liver steatosis evaluated by transient elastography with the controlled attenuation parameter in HIV-infected patients

HIV Medicine

Volumn 17, Issue 10, 2016, Pages 766-773

  Macias J ^a,b   Real, L M ^a,b   Rivero Juarez A ^c   Merchante, N ^a,b   Camacho, A ^c   Neukam, K ^a,b   Rivero, A ^c   Mancebo, M ^a,b   Pineda, J A ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b Instituto de Biomedicina de Sevilla   (Spain)

^c Instituto de Salud Carlos III   (Spain)

Author keywords

body mass index; controlled attenuation parameter; HIV; liver steatosis

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; DARUNAVIR PLUS RITONAVIR; ETRAVIRINE; GLUCOSE; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; ANALYTICAL PARAMETERS; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED ATTENUATION PARAMETER; ELASTOGRAPH; EVALUATION STUDY; FATTY LIVER; FEMALE; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; TRANSIENT ELASTOGRAPHY;

EID: 84989814072     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12384     Document Type: Article

References (25)

1. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010; 52: 71–78.
2. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972–1978.
3. Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19: 585–592.
4. McGovern BH, Ditelberg JS, Taylor LE, Gandhi RT, Christopoulos KA, Chapman S, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43: 365–372.
5. Pascual Pareja JF, Camino A, Larrauri J, López-Diéguez M, Montes ML, González-García J, et al. Factors associated with hepatic steatosis in human immunodeficiency virus and hepatitis C virus coinfected patients. Med Clin (Barc) 2009; 132: 208–213.
6. Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, et al. Incidence and risk factors for steatosis progression in adults coinfected With HIV and Hepatitis C Virus. Gastroenterology 2011; 140: 809–817.
7. Macías J, Berenguer J, Japón MA, Girón-González JA, Rivero A, López-Cortés LF, et al. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients. Hepatology 2012; 56: 1261–1270.
8. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44: 1026–1032.
9. Crum-Cianflone N, Dilay A, Collins G, Asher D, Campin R, Medina S, et al. Nonalcoholic fatty liver disease among HIV-infected persons. J Acquir Immune Defic Syndr 2009; 50: 464–473.
10. Guaraldi G, Squillace N, Stentarelli C, Orlando G, D'Amico R, Ligabue G, et al. Nonalcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics, and predictors. Clin Infect Dis 2008; 47: 250–257.
11. Macías J, Gozález J, Tural C, Ortega-González E, Pulido F, Rubio R, et al. Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients. AIDS 2014; 28: 1279–1287.
12. Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE-guided ultrasonic attenuation measurement for estimating hepatic steatosis. Ultrasound Med Biol 2010; 36: 1825–1835.
13. Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13–20.
14. De Lédinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver Int 2012; 32: 911–918.
15. Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 2012; 32: 902–910.
16. Friedrich-Rust M, Romen D, Vermehren J, Kriener S, Sadet D, Herrmann E, et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325–e331.
17. Vergara S, Macías J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D, et al. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007; 45: 969–974.
18. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835–847.
19. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274–285.
20. Recio E, Cifuentes C, Macías J, Mira JA, Parra-Sánchez M, Rivero-Juárez A, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol 2013; 25: 905–911.
21. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005; 115: 1343–1351.
22. Nguyen NT, Magno CP, Lane KT, Hinojosa MW, Lane JS. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg 2008; 207: 928–934.
23. Maagaard A, Kvale D. Mitochondrial toxicity in HIV-infected patients both off and on antiretroviral treatment: a continuum or distinct underlying mechanisms? J Antimicrob Chemother 2009; 64: 901–909.
24. Venhoff N, Setzer B, Melkaoui K, Walker UA. Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. Antivir Ther 2007; 12: 1075–1085.
25. Blas-García A, Apostolova N, Ballesteros D, Monleón D, Morales JM, Rocha M, et al. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 2010; 52: 115–125.